Ray Therapeutics raised $125 million to advance RTx-015, a first-in-class optogenetic gene therapy granted FDA Regenerative Medicine Advanced Therapy designation for the treatment of retinitis pigmentosa, a rare inherited retinal disease causing progressive vision loss and blindness.
